Oxford biotech firm secures £13.2m to develop world’s first treatment for rare, incurable and deadly disease
A UK biotech company has announced £13m of investment that they believe will fund them through to clinical trials next year of the world’s first treatment for a rare, incurable and deadly disease. The investment has been raised by Oxfordshire-based SynaptixBio, whose aim is to tackle TUBB4a leukodystrophy – a genetic and debilitating condition that mainly…